HOME

HOME

TEAM

TEAM

CAPABILITIES

CAPABILITIES

CONTACT

CONTACT

Begin

Begin

Architects of rare diligence and trusted conviction.

As Founders, we unite scientific depth with institutional rigor—bridging life sciences, finance, and strategy for conscious and visionary capital.

Architects of rare diligence and trusted conviction.

As Founders, we unite scientific depth with institutional rigor—bridging life sciences, finance, and strategy for conscious and visionary capital.

Architects of rare diligence and trusted conviction.

As Founders, we unite scientific depth with institutional rigor—bridging life sciences, finance, and strategy for conscious and visionary capital.

We operate between the lines—where others see data, we decode signal.

We operate between the lines—where others see data, we decode signal.

We operate between the lines—where others see data, we decode signal.

How We Deliver

Dipesh Patel, PhD
Founder & CEO | Strategic Architect

Dipesh Patel, PhD
Founder & CEO | Strategic Architect

Dipesh has dedicated his career to bridging life sciences, finance, and emerging technologies for clients and institutional investors. Most recently, he served as a biotech equity researcher at HC Wainwright, a boutique New York investment bank, covering five major therapeutic areas, producing institutional investment research reports, and tracking more than 150 companies.


Earlier in his career, Dipesh managed a $1.5 billion portfolio, negotiated $900 million in contracts, and closed $20 million in strategic deals—advancing medical innovation and improving healthcare value. He advised early-stage, top-20 biopharma, and Fortune 500 companies across the full healthcare and life sciences value chain—from product to patient to policy—including areas such as drug and device development, clinical trials, strategic intelligence, payor strategy, and commercialization.


Beyond the science and financials, Dipesh is attuned to the structural systems—from healthcare, capital markets, and investment banking to the wider global architectures—that quietly shape outcomes yet are often overlooked in traditional due diligence. This multi-layered lens—integrating science, finance, and systemic dynamics—gives Dipesh a rare vantage point to discern patterns others miss, from micro drug assets to macro forces. This edge informs modern investing and underpins his distinctive approach to diligence, foresight, and strategy.


Ten Sigma was founded to address a fundamental gap: investors are inundated with noise, partial truths, and conflicted advice—especially in the specialized field of life sciences and biotech. Recognizing this, Dipesh envisioned a new model of diligence—sovereign, multi-dimensional, and wisdom-based—designed for visionary investors, family offices, fund managers, and entrepreneurs seeking clarity in complexity and conviction beyond noise.


Ten Sigma’s mission: to provide rare diligence, clarity, and conviction that transcend traditional consensus, uncovering asymmetric opportunities with long-term strategic alignment. Together with Co-Founder Paras Barot, Dipesh anchors Ten Sigma’s commitment to rigorous science, sovereign strategy, and trusted partnership with visionary investors.


Dipesh holds a Ph.D. in Biochemistry (University of North Texas, Northwestern University) and a Post-Doctorate in Bioengineering (UT Southwestern Medical Center), where his published antibody-engineering research (2011) contributed to the scientific foundation of Efgartigimod, later FDA-approved (2021) and commercialized by Argenx (NASDAQ: ARGX).

Dipesh has dedicated his career to bridging life sciences, finance, and emerging technologies for clients and institutional investors. Most recently, he served as a biotech equity researcher at HC Wainwright, a boutique New York investment bank, covering five major therapeutic areas, producing institutional investment research reports, and tracking more than 150 companies.


Earlier in his career, Dipesh managed a $1.5 billion portfolio, negotiated $900 million in contracts, and closed $20 million in strategic deals—advancing medical innovation and improving healthcare value. He advised early-stage, top-20 biopharma, and Fortune 500 companies across the full healthcare and life sciences value chain—from product to patient to policy—including areas such as drug and device development, clinical trials, strategic intelligence, payor strategy, and commercialization.


Beyond the science and financials, Dipesh is attuned to the structural systems—from healthcare, capital markets, and investment banking to the wider global architectures—that quietly shape outcomes yet are often overlooked in traditional due diligence. This multi-layered lens—integrating science, finance, and systemic dynamics—gives Dipesh a rare vantage point to discern patterns others miss, from micro drug assets to macro forces. This edge informs modern investing and underpins his distinctive approach to diligence, foresight, and strategy.


Ten Sigma was founded to address a fundamental gap: investors are inundated with noise, partial truths, and conflicted advice—especially in the specialized field of life sciences and biotech. Recognizing this, Dipesh envisioned a new model of diligence—sovereign, multi-dimensional, and wisdom-based—designed for visionary investors, family offices, fund managers, and entrepreneurs seeking clarity in complexity and conviction beyond noise.


Ten Sigma’s mission: to provide rare diligence, clarity, and conviction that transcend traditional consensus, uncovering asymmetric opportunities with long-term strategic alignment. Together with Co-Founder Paras Barot, Dipesh anchors Ten Sigma’s commitment to rigorous science, sovereign strategy, and trusted partnership with visionary investors.


Dipesh holds a Ph.D. in Biochemistry (University of North Texas, Northwestern University) and a Post-Doctorate in Bioengineering (UT Southwestern Medical Center), where his published antibody-engineering research (2011) contributed to the scientific foundation of Efgartigimod, later FDA-approved (2021) and commercialized by Argenx (NASDAQ: ARGX).

Paras Barot
Co-Founder & Managing Partner | Strategic Architect

Paras Barot
Co-Founder & Managing Partner | Strategic Architect

Paras Barot
Co-Founder & Managing Partner | Strategic Architect

Paras brings over 15 years of global leadership experience from some of the world’s most respected institutions, including Goldman Sachs, HSBC, Munich Re, London Stock Exchange Group, and Marsh McLennan.


Based in Dubai with dual UK–Canadian citizenship, he has directed large-scale corporate programs, advised C-suites, and built governance frameworks across Europe, North America, and the Middle East.


At Goldman Sachs, he oversaw major real estate and infrastructure programs, ensuring strategic intent translated into operational success. At Munich Re, as Global Head of Strategic Planning and PMO, he advised global technology leaders and established governance frameworks across continents. Most recently, as Regional Head of Strategic Programs at Marsh McLennan, Paras led strategic initiatives across Saudi Arabia, India, and the broader IMEA region, balancing regulatory complexity with disciplined cross-border execution.


Beyond his corporate career, Paras is a strategic advisor and investor, serving as a board member at multiple organizations globally, including Halo Therapeutics, a UK-based biotech venture. This dual identity—as both operator and investor—enhances his ability to connect with Ten Sigma’s clients: visionary investors, family offices, fund managers, and entrepreneurs deploying capital and navigating the complexities of long-term wealth, healthcare innovation, and legacy building.


At Ten Sigma, Paras complements the firm’s science-driven insights with institutional credibility, rigorous execution, and global capital networks. His perspective ensures that Ten Sigma’s rare diligence and insights are not only strategic but grounded in the operational and financial realities clients face in life sciences and biotech.


Clients value Paras as a long-term strategic architect and trusted partner—someone who bridges the boardroom dynamics of global institutions with the entrepreneurial mindset of family offices and high-net-worth investors. Together with Dipesh Patel, Paras co-leads Ten Sigma’s mission to deliver rare diligence, clarity and conviction for visionary investors navigating the complex world of life sciences and biotech—positioning the firm as a trusted partner at the intersection of science, capital, and strategy.

Paras brings over 15 years of global leadership experience from some of the world’s most respected institutions, including Goldman Sachs, HSBC, Munich Re, London Stock Exchange Group, and Marsh McLennan.


Based in Dubai with dual UK–Canadian citizenship, he has directed large-scale corporate programs, advised C-suites, and built governance frameworks across Europe, North America, and the Middle East.


At Goldman Sachs, he oversaw major real estate and infrastructure programs, ensuring strategic intent translated into operational success. At Munich Re, as Global Head of Strategic Planning and PMO, he advised global technology leaders and established governance frameworks across continents. Most recently, as Regional Head of Strategic Programs at Marsh McLennan, Paras led strategic initiatives across Saudi Arabia, India, and the broader IMEA region, balancing regulatory complexity with disciplined cross-border execution.


Beyond his corporate career, Paras is a strategic advisor and investor, serving as a board member at multiple organizations globally, including Halo Therapeutics, a UK-based biotech venture. This dual identity—as both operator and investor—enhances his ability to connect with Ten Sigma’s clients: visionary investors, family offices, fund managers, and entrepreneurs deploying capital and navigating the complexities of long-term wealth, healthcare innovation, and legacy building.


At Ten Sigma, Paras complements the firm’s science-driven insights with institutional credibility, rigorous execution, and global capital networks. His perspective ensures that Ten Sigma’s rare diligence and insights are not only strategic but grounded in the operational and financial realities clients face in life sciences and biotech.


Clients value Paras as a long-term strategic architect and trusted partner—someone who bridges the boardroom dynamics of global institutions with the entrepreneurial mindset of family offices and high-net-worth investors. Together with Dipesh Patel, Paras co-leads Ten Sigma’s mission to deliver rare diligence, clarity and conviction for visionary investors navigating the complex world of life sciences and biotech—positioning the firm as a trusted partner at the intersection of science, capital, and strategy.

How We Deliver